Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals' Kalydeco (ivacaftor, VX-770) drug, that targets the defective protein responsible for cystic fibrosis (CF) showed efficacy in Phase 3 trial.
Subscribe to our email newsletter
The data was published in the New England Journal of Medicine (NEJM).
The Phase 3 STRIVE study evaluated 161 patients 12 years or older who received at least one dose of either Kalydeco as a single 150 mg tablet or placebo twice daily.
The data demonstrated improvements in lung function and other measures of disease throughout the 48week study.